Updates from the 2026 SARC Semiannual Meeting before ASCO on May 29th |
|
|
|
We were honored to host another highly attended SARC Semiannual Meeting before ASCO, bringing together investigators, clinicians, industry partners, and patient advocates to discuss the latest developments in sarcoma research and clinical trials. Attendees heard insightful presentations on precision delivery approaches in sarcoma, including antibody-drug conjugates, radiopharmaceuticals, and bispecific antibodies. The meeting also featured updates on SARC’s clinical trial portfolio, committee activities, international collaborations, new educational initiatives, and upcoming studies poised to launch in 2026. The program concluded with an inspiring keynote address from sarcoma survivor, veteran, and author Brandi Benson, highlighting the importance of perseverance and patient advocacy. Videos of the sessions are now available on our website.
We extend our sincere gratitude to our Platinum-Level Sponsors: Aadi Bioscience and Deciphera, and our Gold-Level Sponsors: Cogent Biosciences and Iovance Biotherapeutics. We also appreciate the generous support of our six Silver and Bronze Sponsors. |
|
|
|
SARC to Host Semiannual Meeting at CTOS 2026 |
SARC's second Semiannual Meeting of 2026 will be held in conjunction with the Annual Meeting of the Connective Tissue Oncology Society (CTOS). The meeting will be held on November 18, 2026 from 3:00 - 5:00 pm local time at the Coex Convention Center in Seoul, South Korea.
All CTOS attendees are warmly encouraged to join us for this session! Click here to stay tuned for updates. |
|
| SARC041 Plenary Presentation at ASCO |
SARC041, a phase 3 randomized trial of abemaciclib vs. placebo in advanced DDLPS, led by Dr. Mark Dickson, was selected as one of only five “practice-changing” studies presented at the ASCO 2026 Plenary in Chicago. The study demonstrated a significant improvement in progression-free survival, supporting abemaciclib as a new standard of care in this disease. Click here to learn more.
|
|
| SARC Welcomes Jill Anderson to Board of Directors |
SARC is pleased to welcome Jill Anderson, JD, to its Board of Directors. With deep expertise in legal strategy, governance, and compliance, Anderson brings a valuable perspective to support SARC’s mission of advancing sarcoma research and strengthening collaboration across the field. Click here to learn more about Jill.
|
|
|
|
Now Accepting BVT Early Career Travel Award Applications |
Applications are now open for the Brian Van Tine Early Career Travel Awards, open to applicants globally. Travel awards ($1,000) are available for the SARC Semiannual Meeting at CTOS (deadline: Sept. 18, 2026) and the Sarcoma P31 Meeting (deadline: Oct. 14, 2026). Click here to learn more. |
|
| Sweat Away Sarcoma Charity Event on July 11th |
Celebrate Sarcoma Awareness Month by joining the Second Annual Sweat Away Sarcoma HYROX Charity Event on July 11, 2026, in Florida, Michigan, and Ontario to help raise awareness and support for sarcoma research. Click here to learn how you can participate, donate, or support the effort. |
|
|
SARC Board of Directors Seeks Treasurer |
SARC is currently looking for a strategic thinker to join our Board of Directors as our next Treasurer. This position is a vital part of our leadership team, ensuring our financial health so SARC can continue to develop, facilitate, and accelerate research for the prevention, treatment, and cure of sarcoma. Click here to learn more.
|
|
|
|
SARC TALK: Podcast Series |
Recent episodes of SARC Talk have highlighted the breadth of the sarcoma community, from advances in clinical research to patient advocacy and education. Guests included Drs. Robin Jones, Gina D'Amato, Andrew Rosenberg, Andre Pinto, and Catherine Wilbur; and patient advocate Daphne Edgren.
Listen to SARC Talk. |
|
| SARC TALK: The Patient Experience |
Recent episodes of SARC Talk: The Patient Experience feature Eli Galloway, Sabina Ghebremedhin, McKenna Avery, and Julie-Anne Jean-Pierre sharing their sarcoma journeys. Hosted by Daphne Edgren, the series highlights patient voices and resilience.
Listen to The Patient Experience. |
|
|
Hosted by Drs. Catherine Wilbur and Scott Okuno, this episode of SARC Talk: Journal Club reviews a recent Lancet Oncology phase II trial evaluating cabozantinib plus temozolomide for patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.
Listen to the Journal Club. |
|
|
|
Our Contact Information
*{{Organization Name}}*
*{{Organization Address}}*
*{{Organization Phone}}*
*{{Organization Website}}*
*{{Unsubscribe}}*
|
|
| |
|
|
